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A b s t r a c t
We compared the anti–estrogen receptors (ER) 
SP1, 6F11, and 1D5 antibodies in breast carcinoma 
cases with different ranges of positive cells to evaluate 
whether this could generate different therapies for 
patients. We selected 66 cases of breast cancer, each of 
which was immunostained with the 3 antibodies. 1D5 
was less sensitive than SP1 and 6F11, as seen in 26, 20, 
and 21 negative cases, respectively. Nine cases showed 
differences in endocrine-therapy indications, of which 8 
1D5-negative cases showed low positivity for SP1 and/
or 6F11. However, these cases were prevalently G3, 
progesterone receptor–negative or low-positive, with 
high Ki-67 and positive HER-2 findings, all biological 
features associated with endocrine resistance. Finally 
ER values obtained with these 3 antibodies had no 
implications for chemotherapy.
Estrogen receptors (ER) are powerful predictors of breast 
cancer response to endocrine therapy. In addition, chemo-
therapy is significantly more beneficial in patients with ER-
negative than in ER-positive breast cancer.1 Therefore it is of 
paramount importance to use reliable assays for determining 
ER status to ensure adequate therapy for patients. From the 
1970 to the early 1990s, a ligand-binding assay (LBA) was 
used, which allowed ER levels to be quantitatively assessed. 
The availability of ER antibodies and the advent of heat-
mediated antigen retrieval made it possible to assess ER 
with immunohistochemistry (IHC) on paraffin sections in 
a procedure that is less laborious and less expensive than 
LBA.2 Compared with LBA, ER status determined with IHC 
showed a concordance rate of 70% to 90%; however, it has 
been found consistently to have similar or superior predictive 
and prognostic value.3,4 ER status of breast cancer is cur-
rently assessed in routine diagnosis using IHC on formalin-
fixed, paraffin-embedded tissue. Nevertheless, significant 
variability is seen in laboratories around the world5-7 related 
to preanalytic variables, antigen retrieval techniques, use of 
controls, interpretation, and scoring practices. An important 
issue is the selection of the most reliable antibody. Because 
there is no gold standard, the American Society of Clinical 
Oncology (ASCO)–College of American Pathologists (CAP) 
guidelines recommend the use of antibodies employed in 
studies showing clinical benefit from endocrine therapy in 
ER-positive breast cancer patients. ER antibodies that have 
met these criteria are clones 1D5 (DAKO, Carpinteria, CA), 
6F11 (Vector Laboratories, Burlingame, CA), SP1 (Lab 
Vision, Thermo Fisher Scientific, Kalamazoo, MI), and 
1D5+ER.2.123 (DAKO).3 It is important to note that stud-
ies comparing different antibodies consider discordant cases 
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showing ER staining values lower or higher than 1%, but they 
rarely specify how much these values deviate from this thresh-
old.8-15 For example, a tumor may show 0.5% positive cells 
with an antibody, becoming an ER-negative tumor, and 2% or 
40% with other antibodies, becoming ER positive. However, 
these 2 different conditions may have important differences 
in clinical practice. For example, some authors indicate that 
tumors with ER expression of more than 50% do not show 
significant improvement with the addition of chemotherapy 
to endocrine-therapy.16
The aim of this study was to compare the clinically vali-
dated, most commonly used antibodies for the study of ER 
levels in breast carcinomas and to evaluate whether potential 
differences were significant for therapeutic decisions.
Materials and Methods
From January 2008 to December 2010, 362 consecutive 
infiltrating breast carcinomas were diagnosed at the Institute 
of Pathology of Sacro Cuore Hospital, Negrar, Italy. For study 
purposes, the tumors were subdivided into 4 categories based 
on the rate of ER expression assessed using the clone SP1 
(Ventana Medical Systems, Tucson, AZ) and obtained from 
the pathology records: less than 1%, ER negative3; 1% to 
9%, low ER positive; 10% to 50%, intermediate ER positive 
tumors3,4; and more than 50%,16 highly ER positive. Patient 
age, tumor dimension, grade, vascular invasion, nodes status, 
and Ki-67 and HER-2 values were obtained from the histol-
ogy reports as well. Tissue samples were handled according to 
the ASCO-CAP recommendations3: time from tissue acquisi-
tion to fixation was 20 to 30 minutes; samples were sliced 
at 5-mm intervals and placed in sufficient volume of 10% 
buffered formalin for 8 to 24 hours. 
IHC
The most informative block from each tumor that should 
include normal breast tissue as internal control was selected 
for the IHC reactions using different anti-ER antibodies. 
Reactions with SP1 (Ventana) were repeated. The protocol 
used for each single antibody is reported in ❚Table 1❚.
The presence of some ER-positive nuclei with hetero-
geneous staining pattern of luminal cells and the absence 
of immunoreactivity of myoepithelial, endothelial, and 
inflammatory cells served as positive and negative controls, 
respectively, for all reactions. For assessment of ER expres-
sion using the different antibodies, at least 10 high-power 
fields were randomly selected for each tumor. The percent-
age of positive tumor cells was recorded. Every case was 
assessed by 2 different pathologists (G.B. and L.B.) and, 
in case of significant discordance, revaluation at the multi-
headed microscope was performed by 3 pathologists (G.B., 
L.B., and G.Z.). To evaluate whether the results obtained 
with each single antibody could modify the therapeutic 
approach, a dedicated breast oncologist (M.V.) reviewed 
the clinicopathologic reports of all cases and correlated 
them with the results obtained with each single antibody, 
proposing the more appropriate therapy derived from the 
IHC results.
Statistical Analysis
Data were recorded using Microsoft Excel software 
(Microsoft, Redmond, WA) and transferred to Stata/IC for 
Windows version 11.1 software (StataCorp, College Station, 
TX). The Wilcoxon matched-pair signed-rank test was used to 
compare the ER results found with different antibodies. A P 
value of less than .05 was considered significant. 
Results
Based on the results of clone SP1 (Ventana) and using a 
bimodal classification, 51 cases (14%) were negative (<1% 
ER+) and 311 (86%) were positive (>1% ER+). The posi-
tive cases were subdivided as follows: 12 cases with low 
ER expression (1%-9% ER+); 14 cases showed intermedi-
ate ER positivity (10%-50% ER+); and finally 285 cases 
were highly positive with more than 50% ER+ tumor cells 
❚Figure 1❚. For the clinicopathologic correlation, all cases 
with low and intermediate ER expression were considered, 
and the first 20 cases were selected among the negative and 
highly expressing tumors, for a total of 66 cases ❚Table 2❚.
❚Table 1❚
Protocol Used for Each Single Antibody
Antibody Company Clone Dilution Immunostainer Antigen Retrieval Incubation Detection
Confirm ER Rmab VMS  SP1 PD BenchMarch XT, VMS  CC1 pH 8,2 x 30’ 37°C x 20’ UltraView Universal Dab 
        Detection
ER Mmab  DAKO  1D5 1:100 Bond MaX, Leica ER2 pH 9.0 x 30’ RT x 15’ Bond Polymer Refine Detection
ER Mmab Leica  6F11 1:80 Bond MaX, Leica ER2 pH 9.0 x 30’ RT x 15’ Bond Polymer Refine Detection
ER Rmab, estrogen receptor rabbit monoclonal antibody; ER Mmab, estrogen receptor mouse monoclonal antibody; DAKO, Dako, Carpinteria, CA; Leica, Leica Biosystems, 
Newcastle, England; VMS, Ventana Medical Systems, Tucson, AZ
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SP1 antibody reassessment showed no significant differ-
ences compared with the original reports. The distribution of 
ER staining values, obtained with the 3 antibodies, is shown 
in ❚Table 3❚. Using a threshold of less than 1%, of these 66 
tumors, 20 were negative with SP1, 21 with 6F11, and 26 
with 1D5. The average percentage of stained cells was 36.6%, 
33.6%, and 31.2% for SP1, 6F11, and 1D5, respectively. The 
Wilcoxon test showed that the percentage of cells stained was 
significantly greater with SP1 than 6F11 (P = .002) and 1D5 
(P < .0001) and with 6F11 than 1D5 (P = .0005). The same 
results were obtained using semiquantitated data according to 
the Allred score (data not shown).
In 15 cases, the different percentage of ER-positive nuclei 
obtained with the 3 antibodies led to a shift in the IHC range 
❚Table 4❚. In 9 of these cases (cases 1-9, Table 4), the differ-
ent ER value could influence the therapeutic management, 
❚Table 2❚
Clinical and Pathologic Features of 66 Breast Carcinomas
Feature Finding
Age, y 
   Median 53
   Range 32-93
Size, cm 
   Mean 17
   Range 0.5-8
Histologic type 
   Ductal 57
   Lobular 5
   Others 4
Grading 
   G1 10
   G2 20
   G3 36
Vascular invasions 
   Absent 51
   Present 15
Lymph node metastases 
   Absent 39
   Present 16
   Unknown 11
PR status 
   <1% 26
   ≥1% 40
HER2 status 
   Positive 18
   Negative 48
ER, estrogen receptor; PR, progesterone receptor.
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❚Figure 1❚ Estrogen receptor (ER) distribution of 362 breast 
carcinomas.
❚Table 3❚
ER Values Obtained With the 3 Antibodies
 <1% 1%-9% 10%-50% >50%
SP1 20 12 14 20
6F11 21 10 14 21
1D5 26 9 12 19
ER, estrogen receptor.
❚Table 4❚
Cases With ER Category Shift With the 3 Antibodies
 SP1 6F11 1D5
Case   Size,      Value,    Value,    Value,  
No. Age mm Grading ALM PR Ki-67 HER2 % CT ET % CT ET % CT ET
1 80 40 3 4 0 40 + 0 No No 2 No Yes 5 No Yes
2 71 30 3 0 15 60 – 0 Yes No 5 Yes Yes 0 Yes No
3 41 50 2 0 2 30 – 2 Yes Yes 0 Yes No 0 Yes No
4 57 12 3 0 0 30 + 5 Yes Yes 5 Yes Yes 0 Yes No
5 80 20 3 0 0 30 – 5 No Yes 0 No No 0 No No
6 38 7 3 0 0 60 – 5 Yes Yes 5 Yes Yes 0 Yes No
7 54 18 3 0 1 35 + 8 Yes Yes 2 Yes Yes 0 Yes No
8 81 80 3 2 0 30 + 8 No Yes 0 No No 0 No No
9 42 20 3 14 5 70 – 8 Yes Yes 8 Yes Yes 0 Yes No
10 47 NA 3 NA 30 25 + 8 Yes Yes 20 Yes Yes 8 Yes Yes
11 43 10 2 0 40 15 – 8 Yes Yes 15 Yes Yes 8 Yes Yes
12 74 35 2 0 0 15 – 20 Yes Yes 15 Yes Yes 5 Yes Yes
13 48 25 2 NA 2 5 – 20 Yes Yes 8 Yes Yes 5 Yes Yes
14 42 15 3 10 5 25 + 40 Yes Yes 15 Yes Yes 5 Yes Yes
15 45 25 2 2 8 15 – 60 Yes Yes 60 Yes Yes 40 Yes Yes
ALM, axillary lymph node metastases; CT, chemotherapy; ET, endocrine therapy; NA, not available; –, negative; +, positive.
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with differences seen in indications for endocrine therapy but 
not chemotherapy. In particular, 2 SP1-negative were 6F11- 
and/or 1D5-positive cases; 3 6F11-negative were SP1- and/
or 1D5-positive cases; 8 1D5-negative were SP1- and/or 
6F11-positive cases. All cases that would receive a therapeu-
tic change were in the category of tumors with ER staining 
values between 0% and 9% ❚Image 1❚.
Discussion
In this study, we showed that the ER expression 
obtained using SP1, 6F11, and 1D5 antibodies in breast car-
cinomas could modify the therapeutic approach for patients 
with breast cancer. Using the SP1 antibody in routine 
diagnoses, we could divide our case series into positive 
and negative cases using a bimodal distribution with a 1% 
cutoff as suggested in the literature.17-19 However, studies 
on ER status using LBA20 or polymerase chain reaction21 
revealed a broad range of ER values among ER-positive 
breast cancer. The amount of ER demonstrated with the 
IHC assay may be as much a function of preanalytic fac-
tors and assay sensitivity.17 It may be possible that the 
dichotomization of a continuous variable can result in loss 
of clinical information.22 Because the ER bimodal distri-
bution results in a shift of cases with low or intermediate 
positive ER to higher levels,17 the likely consequence is a 
reduction of chemotherapy indications.
A B
C D
❚Image 1❚ Example of a ductal carcinoma (A, H&E) with different immunostaining expression for SP1 (8%; B), 6F11 (2%; C), 
and 1D5 (negative; D).
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The staining comparison of the 3 antibodies showed that 
1D5 was less sensitive than SP1 and 6F11. In addition, the per-
centage of stained cells was significantly greater with SP1 than 
6F11/1D5 and with 6F11 than 1D5. Studies have compared 
different anti-ER antibodies in breast carcinoma. Vassallo et 
al15 (20 cases), Arihiro et al8 (89 cases), and Kaplan et al11 
(592 cases) showed no significant differences in sensitivity 
between 1D5 and 6F11. In particular, Kaplan et al11 showed a 
97.5% concordance rate, even though 6F11 stained a signifi-
cantly higher percentage of cells and more intensely. Cheang 
et al10 demonstrated that SP1 is superior to 1D5 for identifying 
patients with good prognosis among those with ER-positive 
breast carcinomas. Although results of this study are in line 
with the results of Treaba et al,14 the study has been criticized 
because it was conducted on tissue microarray specimens 
from frozen material left over after LBA; this artifact may dif-
ferentially affect the epitope targeted by 1D5 rather than SP1. 
This study also had a larger-than-expected proportion of LBA-
positive/IHC-negative tumors.23 A subsequent study compar-
ing SP1 and 1D5 immunostaining results in 508 formalin-fixed 
and paraffin-embedded breast cancers showed a 99.6% concor-
dance rate, with only 2 discordant SP1-positive/1D5-negative 
cases. These 2 cases included poorly differentiated invasive 
carcinoma showing very rare and weakly positive nuclei 
with 1D5 (<1%) and 5% and 8% positive nuclei with SP1, 
respectively.9 Few studies comparing 6F11 and SP1 showed 
no significant sensitivity differences between the 2 antibod-
ies.12,13 However, one of these studies showed that SP1 stained 
a significantly higher percentage of cells and more intensely.13 
Finally the United Kingdom National External Quality Assess-
ment Scheme found that laboratories using 6F11 and SP1 had 
more satisfactory performances than those using 1D5.24 
All the aforementioned studies analyzed the performances 
of anti-ER antibodies on nonselected cases, and none evalu-
ated the effect on therapeutic management based on different 
staining values. For this reason, we focused our attention on 
selected cases with different ranges of ER positivity, using 
thresholds related to therapeutic indications. In 9 of our cases 
(Table 4, cases 1-9) the indication for endocrine therapy was 
influenced by the antibodies used for IHC staining because 
the tumor was considered negative with one (<1% ER+) and 
positive with another (1% to 9% ER+) antibody. These cases 
were prevalently G3, progesterone receptor–negative or low-
positive, with high Ki-67 and positive HER-2. All these bio-
logical features are associated with endocrine-resistance25-27 
and suggest chemotherapy as a useful option.
The threshold used to define ER positivity is debatable. 
Although the ASCO-CAP panel recommended considering 
endocrine therapy in patients whose breast tumor shows at 
least 1% ER+ cells, they recognize that these recommenda-
tions will result in a slight increase in the application of 
endocrine therapy in some cases. They also recognize that it 
is reasonable for oncologists to discuss the pros and cons of 
endocrine therapy with patients whose tumor contains low 
levels of ER on IHC (1% to 10% weakly positive cells) and to 
make an informed decision based on the balance.3 In a recent 
retrospective study on 1,257 patients with breast cancer who 
had ER staining of less than 10%, the authors concluded that 
the prognosis for tumors with low ER expression (1%-10%), 
especially ER staining of 1% to 5%, does not differ signifi-
cantly from tumors with undetectable ER levels (<1%).28
In conclusion, this study demonstrated higher sensitivity 
of anti-ER SP1 and 6F11 clones compared with 1D5 clone. 
However, cases negative with anti-ER 1D5 showed low posi-
tivity (1% to 9%) with SP1 and 6F11 and were also related to 
other biological features associated with endocrine resistance. 
The ER values obtained with these 3 antibodies had no impli-
cations for chemotherapy.
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